<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24602490</article-id><article-id pub-id-type="pmc">4014809</article-id><article-id pub-id-type="publisher-id">cc13742</article-id><article-id pub-id-type="doi">10.1186/cc13742</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Cytomegalovirus reactivation in critically ill burn patients: it&#x02019;s time to worry about it!</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Bordes</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>bordes.julien@neuf.fr</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Goutorbe</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>goutorbephil@live.fr</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Montcriol</surname><given-names>Ambroise</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>ambroise.montcriol@free.fr</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Boret</surname><given-names>Henry</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>boret.henry@neuf.fr</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Dantzer</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>eric.dantzer@wanadoo.fr</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Meaudre</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>eric.meaudre@club-internet.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Intensive Care and Anesthesiology, Teaching Military Sainte Anne Hospital, BCRM Toulon, BP n&#x000b0;600, 83800 Toulon Cedex 9, France</aff><aff id="I2"><label>2</label>Burn Care Center, Teaching Military Sainte Anne Hospital, BCRM Toulon, BP n&#x000b0;600, 83800 Toulon Cedex 9, France</aff><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>25</day><month>2</month><year>2014</year></pub-date><volume>18</volume><issue>1</issue><fpage>410</fpage><lpage>410</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>BioMed Central Ltd.</copyright-holder></permissions><self-uri xlink:href="http://ccforum.com/content/18/1/410"/></article-meta><notes><p>See related research by Heininger <italic>et al</italic>., <ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/15/2/R77">http://ccforum.com/content/15/2/R77</ext-link>.</p></notes></front><body><sec><title/><p>Cytomegalovirus (CMV) reactivation is widely documented in non-immunosuppressed critically ill patients and was reported in a previous issue of <italic>Critical Care</italic> to be associated with poor outcomes [<xref ref-type="bibr" rid="B1">1</xref>]. Although the question of the causative role of CMV remains under debate, a clinical trial aiming to evaluate the efficacy and safety of prophylactic treatment for prevention of CMV reactivation in immunocompetent patients in critical care has started [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>To date, few data on patients with burns have been published. However, we know that patients with burns are predisposed to herpes virus infection and that they are good &#x02018;candidates&#x02019; for CMV reactivation. As expected, data show a high CMV reactivation rate in patients with burns, from 55&#x000a0;% to 71&#x000a0;% [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Moreover, CMV reactivation seems to be intense, as 67&#x000a0;% of patients reactivated CMV with a plasma viral load of greater than 1,000 copies/mL and 33&#x000a0;% did so with a viral load of greater than 10,000 copies/mL in the study by Bordes and colleagues [<xref ref-type="bibr" rid="B4">4</xref>]. However, available data in the literature are extracted from a subgroup of 20 patients with burns among a cohort of 120 critically ill patients for the study by Limaye and colleagues [<xref ref-type="bibr" rid="B3">3</xref>] and from a cohort of 29 patients with severe burns for the study by Bordes and colleagues [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>These preliminary results emphasize the fact that it is absolutely necessary to better investigate the natural history of CMV reactivation in burns, as antiviral prophylaxis is being evaluated in critically ill patients. Indeed, if antiviral therapy is proved to be efficient on the CMV reactivation, should we treat more than 50&#x000a0;% of our burn patients with antiviral treatment?</p><p>That is why we think that CMV reactivation still has to be studied in patients with burns, with the aim of answering the following questions:</p><p>&#x02022; Is CMV reactivation as frequent as previously reported in patients with severe burns?</p><p>&#x02022; What are the risk factors for CMV reactivation in patients with burns?</p><p>&#x02022; Is CMV reactivation associated with a poor outcome?</p><p>&#x02022; And is there a quantitative association between CMV reactivation and poor outcome?</p><p>The community of burn caregivers should promote large and prospective cohorts of patients in order to investigate CMV reactivation in severe burns as a first step to support the potential indication of antiviral therapy in the coming years.</p><sec><title>Abbreviations</title><p>CMV: Cytomegalovirus.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Heininger</surname><given-names>A</given-names></name><name><surname>Haeberle</surname><given-names>H</given-names></name><name><surname>Fischer</surname><given-names>I</given-names></name><name><surname>Beck</surname><given-names>R</given-names></name><name><surname>Riessen</surname><given-names>R</given-names></name><name><surname>Rohde</surname><given-names>F</given-names></name><name><surname>Meisner</surname><given-names>C</given-names></name><name><surname>Jahn</surname><given-names>G</given-names></name><name><surname>Koenigsrainer</surname><given-names>A</given-names></name><name><surname>Unertl</surname><given-names>K</given-names></name><name><surname>Hamprecht</surname><given-names>K</given-names></name><article-title>Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis</article-title><source>Crit Care</source><year>2011</year><volume>15</volume><fpage>R77</fpage><pub-id pub-id-type="doi">10.1186/cc10069</pub-id><pub-id pub-id-type="pmid">21362193</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Millar</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>SC</given-names></name><name><surname>Cowley</surname><given-names>N</given-names></name><name><surname>Moss</surname><given-names>P</given-names></name><name><surname>Osman</surname><given-names>H</given-names></name><name><surname>Bion</surname><given-names>JF</given-names></name><article-title>Anti-viral prophylaxis for prevention of cytomegalovirus reactivation in immunocompetent patients in critical care [abstract]</article-title><source>Intensive Care Med</source><year>2013</year><volume>39</volume><issue>suppl 2</issue><fpage>201</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">24096313</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Limaye</surname><given-names>AP</given-names></name><name><surname>Kirby</surname><given-names>KA</given-names></name><name><surname>Rubenfeld</surname><given-names>GD</given-names></name><name><surname>Leisenring</surname><given-names>WM</given-names></name><name><surname>Bulger</surname><given-names>EM</given-names></name><name><surname>Neff</surname><given-names>MJ</given-names></name><name><surname>Gibran</surname><given-names>NS</given-names></name><name><surname>Huang</surname><given-names>ML</given-names></name><name><surname>Santo Hayes</surname><given-names>TK</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Boeckh</surname><given-names>M</given-names></name><article-title>Cytomegalovirus reactivation in critically ill immunocompetent patients</article-title><source>JAMA</source><year>2008</year><volume>300</volume><fpage>413</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">18647984</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Bordes</surname><given-names>J</given-names></name><name><surname>Maslin</surname><given-names>J</given-names></name><name><surname>Prunet</surname><given-names>B</given-names></name><name><surname>D&#x02019;Aranda</surname><given-names>E</given-names></name><name><surname>Lacroix</surname><given-names>G</given-names></name><name><surname>Goutorbe</surname><given-names>P</given-names></name><name><surname>Dantzer</surname><given-names>E</given-names></name><name><surname>Meaudre</surname><given-names>E</given-names></name><article-title>Cytomegalovirus infection in severe burn patients monitoring by real-time polymerase chain reaction: a prospective study</article-title><source>Burns</source><year>2011</year><volume>37</volume><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.burns.2010.11.006</pub-id><pub-id pub-id-type="pmid">21237572</pub-id></mixed-citation></ref></ref-list></back></article>